AMPH
Amphastar Pharmaceuticals, Inc.
AMPH has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over AMPH overall, supported by stronger fundamentals and stronger modeled upside.
AMPH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Stable |
AMPH's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
AMPH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 8.8x | $28.87 | — |
| Cheap | 12x | $25.21 | -13% |
| Current | 13x | $28.87 | — |
| Fair | 19x | $40.83 | +41% |
| Expensive | 89x | $196 | +578% |
Historical ranges are pointers, not guarantees.
AMPH's PE is in its cheap range at 13x. If earnings grow as analysts expect, today's price would be 8.8x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over AMPH in the historical PE scenario, which offers more potential upside but is not a forecast.
AMPH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for AMPH, with profitability holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over AMPH on the outlook, with more favorable profitability expectations.
AMPH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.28 | +50% |
| Q3 2026 | $2.19 | -3.1% |
| Q2 2026 | $1.69 | -37% |
| Q1 2026 | $1.66 | -40% |
| Q4 2025 | $2.03 | -34% |
| Q3 2025 | $2.26 | -25% |
| Q2 2025 | $2.67 | -15% |
| Q1 2025 | $2.76 | -5.2% |
| Q4 2024 | $3.06 | +18% |
AMPH's earnings per share have fallen from their peak: $2.19 over the past year, against $3.15 in mid-2024.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over AMPH on earnings, with more consistent year-over-year improvement.
AMPH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $207.6M | +8.2% |
| Q2 2026 | $183.9M | +5.4% |
| Q1 2026 | $171.2M | +0.4% |
| Q4 2025 | $183.1M | -1.8% |
| Q3 2025 | $191.8M | +0.3% |
| Q2 2025 | $174.4M | -4.4% |
| Q1 2025 | $170.5M | -0.8% |
| Q4 2024 | $186.5M | +4.7% |
AMPH's revenue grew through 2024 and has held roughly level since: $208M last quarter, up 8.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 24% | +11 points |
| Q2 2026 | 22% | -2.6 points |
| Q1 2026 | 8% | -14 points |
| Q4 2025 | 19% | -4.8 points |
| Q3 2025 | 13% | -17 points |
| Q2 2025 | 24% | -6.1 points |
| Q1 2025 | 22% | -6.1 points |
| Q4 2024 | 24% | -6.1 points |
AMPH has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over AMPH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
AMPH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $33.4M | -29% |
| Q2 2026 | $42.7M | +71% |
| Q1 2026 | $38.3M | +57% |
| Q4 2025 | $24.6M | +48% |
| Q3 2025 | $47.2M | +2.3% |
| Q2 2025 | $25M | -60% |
| Q1 2025 | $24.4M | -48% |
| Q4 2024 | $16.6M | +15% |
AMPH generated $139M in free cash flow over the past year, up 23% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over AMPH on cash flow, with more consistent year-over-year improvement.
AMPH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.9% | -848K shares |
| 1 year | -9% | -4.3M shares |
| 3 years | -20% | -10.5M shares |
| 5 years | -13% | -6.6M shares |
| Available history | -7.4% | -3.5M shares |
AMPH has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $438,000 |
| Q2 2026 | $45.2M |
| Q1 2026 | $29.5M |
| Q4 2025 | $20.5M |
| Q3 2025 | $4.9M |
| Q2 2025 | $39.2M |
| Q1 2025 | $11M |
| Q4 2024 | $42M |
AMPH spent $96M buying back its own shares over the past year, down 1.5% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
AMPH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | 2.3x | Moderate |
| Q1 2026 | 2.5x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.9x | Healthy |
| Q2 2025 | 1.8x | Healthy |
| Q1 2025 | 1.8x | Healthy |
| Q4 2024 | 1.9x | Healthy |
AMPH's net debt is about 2.1 years of its operating earnings (EBITDA), up from 1.9 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over AMPH on leverage, with a lower net debt burden relative to earnings.
AMPH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 67.2 | Neutral |
| Stochastic | 86.2 | Overbought |
AMPH's weekly RSI is 67 (neutral) and its Stochastic is 86 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
AMPH PE vs Healthcare Sector
| Metric | AMPH | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 49% below |
| PE % | 25 | 29 | 4 pts below |
AMPH is trading at 13x earnings, a 49% discount to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over AMPH on valuation relative to its sector.
AMPH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $26.8 | 7.8% above |
| 20 week MA | $23.4 | 24% above |
| 50 week MA | $23.0 | 26% above |
| 100 week MA | $25.3 | 14% above |
| 200 week MA | $35.8 | 19% below |
AMPH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 19% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over AMPH on trend strength, trading above more of its moving averages.
AMPH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.2 | $19.1 | -0.3% |
| 2021 | $19.1 | $22.6 | +18% |
| 2022 | $22.6 | $28.7 | +27% |
| 2023 | $28.7 | $61.9 | +116% |
| 2024 | $61.9 | $37.8 | -39% |
| 2025 | $37.8 | $27.1 | -28% |
| 2026 YTD | $27.1 | $28.9 | +6.5% |
AMPH has finished lower in three of the last six years. It's up 6.5% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over AMPH on returns for 2026, with the stronger performance.